Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series : World's leading Event Organizer

Back

Borovikov Artem

Borovikov Artem

I.M. Sechenov First Moscow State Medical University, Russia

Title: Autoimmunity and autoimmune disorders-genomics and genome-based applications to set up biobanks networks and to secure genetic passportization

Biography

Biography: Borovikov Artem

Abstract

The number of people suffering from autoimmune diseases increases every year. Active growth related with two problems: Initial symptoms are often intermittent, unspecific until the condition becomes acute and a shortage of methods for the preclinical diagnostics. Discovering new biomarkers for early prediction and diagnosis is a chance for control rate and courses of autoimmune disease. The development of most autoimmune diseases includes a strong heritable component. Genetic contribution to autoimmunity is often complex interactions different genes and their products. Genomics based research can give a lot of new information about the potential risks and compounds, those can be optimal biomarkers of early prediction and indicate stage more accurately. But researchers need a lot of data to achieve real goals. Today most of the studies usually are disease-specific and limited in resources. More information-sharing and crossover among research projects on different autoimmune diseases is needed to stimulate them effectiveness. Biobanking is a primary tool for ensuring easy availability of high-quality biomaterial collections that combine essential samples and epidemiological, clinical and research data for autoimmune disease. In some cases, individual biobanks often do not have the required number of well-characterized donor materials. Possibly, the solution of this problem is networking some biobanks merging their records and evaluating them collectively. This method gives access to larger cohorts than would be possible through individual biobanks. It is opening new horizons for researchers but creating networks makes a new problem with legal, ethical and financial aspects of them work.